FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897311551> ?p ?o ?g. }

• W2897311551 endingPage "e0205640" @default.
• W2897311551 startingPage "e0205640" @default.
• W2897311551 abstract "For managing overactive bladder (OAB), mirabegron, a β3 adrenergic receptor agonist, is typically used as second-line pharmacotherapy after antimuscarinics. Therefore, patients initiating treatment with mirabegron and antimuscarinics may differ, potentially impacting associated clinical outcomes. When using observational data to evaluate real-world safety and effectiveness of OAB treatments, residual bias due to unmeasured confounding and/or confounding by indication are important considerations. Falsification analysis, in which clinically irrelevant endpoints are tested as a reference, can be used to assess residual bias. The objective in this study was to compare baseline cardiovascular risk among OAB patients by treatment, and assess the presence of residual bias via falsification analysis of OAB patients treated with mirabegron or antimuscarinics, to determine whether clinically relevant comparisons across groups would be feasible. Linked electronic health record and claims data (Optum/Humedica) for OAB patients in the United States from 2011-2015 were available, with index defined as first date of OAB treatment during this period. Unadjusted characteristics were compared across groups at index and propensity-matching conducted. Falsification endpoints (hepatitis C, shingles, community-acquired pneumonia) were compared between groups using odds ratios (ORs) and 95% confidence intervals (CI). The study identified 10,311 antimuscarinic- and 408 mirabegron-treated patients. Mirabegron patients were predominantly older males, with more comorbidities. The analytic sample included 1,188 antimuscarinic patients propensity-matched to 396 mirabegron patients; after matching, no significant baseline differences remained. Estimates of falsification ORs were 0.7 (CI:0.3-1.7) for shingles, 1.5 (CI:0.3-8.2) for hepatitis C, 0.8 (CI:0.4-1.8) and 0.9 (CI:0.6-1.4) for pneumonia. While propensity matching successfully balanced observed covariates, wide CIs prevented definitive conclusions regarding residual bias. Accordingly, further observational comparisons by treatment group were not pursued. In real-world analysis, bias-detection methods could not confirm that differences in cardiovascular risk in patients receiving mirabegron versus antimuscarinics were fully adjusted for, precluding clinically relevant comparisons across treatment groups." @default.
• W2897311551 created "2018-10-26" @default.
• W2897311551 creator A5016871069 @default.
• W2897311551 creator A5029849735 @default.
• W2897311551 creator A5037835747 @default.
• W2897311551 creator A5038504638 @default.
• W2897311551 creator A5053829326 @default.
• W2897311551 creator A5076345301 @default.
• W2897311551 creator A5078888395 @default.
• W2897311551 date "2018-10-16" @default.
• W2897311551 modified "2023-10-16" @default.
• W2897311551 title "Cardiovascular risk profile in individuals initiating treatment for overactive bladder – Challenges and learnings for comparative analysis using linked claims and electronic medical record databases" @default.
• W2897311551 cites W101552665 @default.
• W2897311551 cites W1835490971 @default.
• W2897311551 cites W1894715927 @default.
• W2897311551 cites W1967347194 @default.
• W2897311551 cites W1970981040 @default.
• W2897311551 cites W1971078174 @default.
• W2897311551 cites W1984454461 @default.
• W2897311551 cites W1993609219 @default.
• W2897311551 cites W2001385630 @default.
• W2897311551 cites W2014075072 @default.
• W2897311551 cites W2053490249 @default.
• W2897311551 cites W2053975254 @default.
• W2897311551 cites W2067945145 @default.
• W2897311551 cites W2071052332 @default.
• W2897311551 cites W2082431080 @default.
• W2897311551 cites W2082897746 @default.
• W2897311551 cites W2107806473 @default.
• W2897311551 cites W2109238714 @default.
• W2897311551 cites W2110991424 @default.
• W2897311551 cites W2120751691 @default.
• W2897311551 cites W2133057011 @default.
• W2897311551 cites W2142912667 @default.
• W2897311551 cites W2144113585 @default.
• W2897311551 cites W2145888765 @default.
• W2897311551 cites W2151418564 @default.
• W2897311551 cites W2160423442 @default.
• W2897311551 cites W2164445871 @default.
• W2897311551 cites W2189252000 @default.
• W2897311551 cites W2318585764 @default.
• W2897311551 cites W2343099020 @default.
• W2897311551 cites W2368205585 @default.
• W2897311551 cites W2410489186 @default.
• W2897311551 cites W305196288 @default.
• W2897311551 doi "https://doi.org/10.1371/journal.pone.0205640" @default.
• W2897311551 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6191128" @default.
• W2897311551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30325968" @default.
• W2897311551 hasPublicationYear "2018" @default.
• W2897311551 type Work @default.
• W2897311551 sameAs 2897311551 @default.
• W2897311551 citedByCount "4" @default.
• W2897311551 countsByYear W28973115512020 @default.
• W2897311551 countsByYear W28973115512022 @default.
• W2897311551 crossrefType "journal-article" @default.
• W2897311551 hasAuthorship W2897311551A5016871069 @default.
• W2897311551 hasAuthorship W2897311551A5029849735 @default.
• W2897311551 hasAuthorship W2897311551A5037835747 @default.
• W2897311551 hasAuthorship W2897311551A5038504638 @default.
• W2897311551 hasAuthorship W2897311551A5053829326 @default.
• W2897311551 hasAuthorship W2897311551A5076345301 @default.
• W2897311551 hasAuthorship W2897311551A5078888395 @default.
• W2897311551 hasBestOaLocation W28973115511 @default.
• W2897311551 hasConcept C126322002 @default.
• W2897311551 hasConcept C142724271 @default.
• W2897311551 hasConcept C156957248 @default.
• W2897311551 hasConcept C17923572 @default.
• W2897311551 hasConcept C204787440 @default.
• W2897311551 hasConcept C23131810 @default.
• W2897311551 hasConcept C2778164427 @default.
• W2897311551 hasConcept C2778941218 @default.
• W2897311551 hasConcept C71924100 @default.
• W2897311551 hasConcept C77350462 @default.
• W2897311551 hasConceptScore W2897311551C126322002 @default.
• W2897311551 hasConceptScore W2897311551C142724271 @default.
• W2897311551 hasConceptScore W2897311551C156957248 @default.
• W2897311551 hasConceptScore W2897311551C17923572 @default.
• W2897311551 hasConceptScore W2897311551C204787440 @default.
• W2897311551 hasConceptScore W2897311551C23131810 @default.
• W2897311551 hasConceptScore W2897311551C2778164427 @default.
• W2897311551 hasConceptScore W2897311551C2778941218 @default.
• W2897311551 hasConceptScore W2897311551C71924100 @default.
• W2897311551 hasConceptScore W2897311551C77350462 @default.
• W2897311551 hasFunder F4320307769 @default.
• W2897311551 hasIssue "10" @default.
• W2897311551 hasLocation W28973115511 @default.
• W2897311551 hasLocation W28973115512 @default.
• W2897311551 hasLocation W28973115513 @default.
• W2897311551 hasLocation W28973115514 @default.
• W2897311551 hasLocation W28973115515 @default.
• W2897311551 hasOpenAccess W2897311551 @default.
• W2897311551 hasPrimaryLocation W28973115511 @default.
• W2897311551 hasRelatedWork W103747493 @default.
• W2897311551 hasRelatedWork W1989803330 @default.
• W2897311551 hasRelatedWork W2111245922 @default.
• W2897311551 hasRelatedWork W2396000345 @default.
• W2897311551 hasRelatedWork W2581550094 @default.
• W2897311551 hasRelatedWork W2782541797 @default.

• next